Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer

被引：13

作者：

Ambrosio, Allison J. ^{[1
]}

Suzin, Daphne ^{[1
]}

Palmer, Edwin L. ^{[1
]}

Penson, Richard T. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2014年 / 7卷 / 04期

关键词：

chemotherapy; EC145; EC20; etarfolatide; novel; PEGYLATED LIPOSOMAL DOXORUBICIN; PHASE-III TRIAL; EPITHELIAL OVARIAN; CLINICAL-TRIAL; FALLOPIAN-TUBE; RECURRENT; SURVIVAL; FARLETUZUMAB; CHEMOTHERAPY; BINDING;

D O I：

10.1586/17512433.2014.909723

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Seminal advances in the treatment of cancer have been achieved because of drug development in ovarian cancer; notably the developments of platinums and taxanes. However, no new drug has been FDA approved for ovarian cancer since 2006, and the approval of an antiangiogenic agent for ovarian cancer in the US has stalled. Predicting the next breakthrough is a high risk and highly expensive venture. One of the most promising prospects is folate-receptor (FR)-targeted therapy, given the high expression in FR ovarian cancer. We review the development of vintafolide (EC145), a folic acid-desacetylvinblastine conjugate, the predictive utility of a FR-targeted imaging agent, technetium-(99)m-etarfolatide (EC20), the challenges in proving survival advantage, and other approaches to exploiting FR as a target in ovarian cancer.

引用

页码：443 / 450

页数：8

共 47 条

[1]

[Anonymous], AACR 2008 99 AACR AN

[2]

[Anonymous], 2013, American Cancer Society Cancer Facts Figures

[3]

[Anonymous], J CLIN ONCOL S

[4]

ANTONY AC, 1992, BLOOD, V79, P2807

[5] Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer [J].

Armstrong, Deborah K. ;

White, Allen J. ;

Weil, Susan C. ;

Phillips, Martin ;

Coleman, Robert L. .

GYNECOLOGIC ONCOLOGY, 2013, 129 (03) :452-458

[6] Making the best of PARP inhibitors in ovarian cancer [J].

Banerjee, Susana ;

Kaye, Stan B. ;

Ashworth, Alan .

NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (09) :508-519

[7] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[8] RESPONSE OF PATIENTS IN PHASE-II STUDIES OF CHEMOTHERAPY IN OVARIAN-CANCER - IMPLICATIONS FOR PATIENT TREATMENT AND THE DESIGN OF PHASE-II TRIALS [J].

BLACKLEDGE, G ;

LAWTON, F ;

REDMAN, C ;

KELLY, K .

BRITISH JOURNAL OF CANCER, 1989, 59 (04) :650-653

[9] Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG158) and an update on GOG0 182-ICON5 [J].

Bookman, MA ;

Greer, BE ;

Ozols, RF .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (06) :735-740

[10] Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation [J].

Burzykowski, Tomasz ;

Buyse, Marc .

PHARMACEUTICAL STATISTICS, 2006, 5 (03) :173-186

← 1 2 3 4 5 →